Andrea N Burnett-Hartman1, Renda Soylemez Wiener2,3. 1. Institute for Health ResearchKaiser Permanente ColoradoAurora, Colorado. 2. Center for Healthcare Organization and Implementation ResearchEdith Nourse Rogers Memorial VA HospitalBedford, Massachusettsand. 3. The Pulmonary CenterBoston University School of MedicineBoston, Massachusetts.
After the results of the NLST (National Lung Screening Trial)
(1) and the U.S. Preventive Services Task
Force grade B recommendation for lung cancer screening with annual low-dose computed
tomography (LDCT) (2), healthcare systems began
implementing lung cancer screening. Despite evidence for a reduction in lung cancermortality associated with lung cancer screening (1), uptake of lung cancer screening has remained low, especially among
underserved populations (3). Given that lung
cancer disproportionately affects populations that struggle with poverty, lower levels
of education, and reduced access to care (4), it
is important to develop effective interventions to increase lung cancer screening in
these underserved, hard-to-reach populations.In this issue of the Journal, Quaife and colleagues (pp. 965–975) presented the results of a randomized trial aimed at
increasing lung cancer screening uptake (5). In
both arms of the trial, participants received brief letters from their primary care
provider with a prescheduled time for a screening LDCT and an informational flyer. The
difference was in the flyer received: the control arm received a traditional text-based
flyer (six pages) containing detailed information about lung cancer screening, and the
intervention arm included a two-page flyer with less-dense information and more images,
hypothesized to be more patient friendly. In both arms, participants had the opportunity
to ask questions and discuss lung cancer screening in person with a clinician on the day
of the scheduled LDCT appointment. The authors hypothesized that the stepped approach to
information provision represented by the intervention arm would increase screening
uptake compared with the control arm.Although the trial results showed no difference in lung cancer screening uptake between
the two study arms, this study had several strengths that merit consideration. First of
all, this study should be commended for its focus on a high-risk and understudied
population; 61% of the study population met deprivation index criteria for being in the
most deprived quintile, another 35% were in the second most deprived quintile, and 75%
were current smokers. Thus, the study population targeted those who are at high risk for
lung cancer mortality but who were medically underserved far more effectively than the
NLST. In order for lung cancer screening to close, and not widen, health disparities in
lung cancer mortality, it must reach populations similar to the ones included in this
trial. Second, the approach used in both arms of this study, which consisted of a series
of patient mailings, was low burden to patients and the healthcare system. This is an
important consideration, because resource-intensive, complex interventions may be
difficult to sustain after study completion (6).
Finally, the study’s randomized design controlled for potential confounding,
allowing for evaluation of the intervention between comparable groups.Despite these strengths, there are also potential concerns about the intervention
selected for this study. First, there is conflicting evidence regarding its potential
for success in this type of healthcare setting and with underserved populations.
Although some studies suggest that carefully designed, tailored leaflets can positively
affect cancer screening knowledge, attitudes, and informed decision making (7, 8),
other studies have failed to show improved cancer screening uptake with leaflets (9, 10).
Second, the design of the leaflet in the Quaife and colleagues study may thwart true
shared decision making (5). This concern is
particularly important, because shared decision making for lung cancer screening is
recommended by guidelines and required for reimbursement by the Centers for Medicare and
Medicaid Services. The intervention leaflet only mentions potential benefits of lung
cancer screening, with no mention of potential harms. Although there is an opportunity
for a fuller discussion of benefits and harms when the individual presents for their
LDCT appointment, this opportunity may come too late. Once people have already taken the
time to arrange their schedule and transportation to come in person for their LDCT
appointment, they have likely already made up their mind to proceed, even if they learn
new information about potential harms that might have otherwise led them to decline
screening.Regardless of the merits or deficiencies of the intervention leaflet, this trial reported
an impressive rate of lung cancer screening uptake. Although multiple observational
studies show rates of lung cancer screening hovering at <10% of eligible
individuals in the U.S. population (3, 11), the study by Quaife and colleagues achieved
screening rates of >50% (5). Although some
of this difference may be attributed to all participants in the Quaife and colleagues
study having established primary care providers (which is not the case for
population-based studies), the proactive approach of mailing eligible individuals
letters with scheduled appointments for LDCT examinations and informational flyers may
also have been effective at increasing uptake among this socioeconomically deprived
population (5).Future research to improve lung cancer screening uptake and decision making should
capitalize on lessons learned from the Quaife and colleagues study and from other cancer
screening contexts (5). Prior healthcare systems
research and theory suggest that multilevel cancer screening interventions are
associated with the largest improvements in cancer screening outcomes (12). Future approaches could, for example, pair
the approach used by Quaife and colleagues (5)
of proactively sending letters with LDCT appointment times and informational flyers to
eligible individuals with other strategies shown to increase uptake of screening in
underserved communities, such as the use of nurse navigators (13). Communication materials sent to underserved populations
should be tailored to take into account reading level, medical fluency, language
preference, and cultural beliefs and considerations. For example, studies of underserved
Appalachian smokers highlight the importance of tailored messages to raise hope rather
than invoke stigma in lung cancer screening materials (14). Finding the optimal balance of information on benefits and harms of
lung cancer screening to support shared decision making without overwhelming patients
from disadvantaged backgrounds remains challenging, but lessons can be learned from
prior breast and prostate cancer screening studies (7, 15). Thus, by using historical
lessons learned from cancer screening in other organ sites, healthcare systems can
develop and test lung cancer screening interventions to ensure that lung cancer
screening is implemented in a way that addresses, rather than exacerbates, disparities
in lung cancer mortality.
Authors: Heidi A van Vugt; Monique J Roobol; Lionne D F Venderbos; Evelien Joosten-van Zwanenburg; Marie-Louise Essink-Bot; Ewout W Steyerberg; Chris H Bangma; Ida J Korfage Journal: Eur J Cancer Date: 2010-02 Impact factor: 9.162
Authors: Samantha L Quaife; Mamta Ruparel; Jennifer L Dickson; Rebecca J Beeken; Andy McEwen; David R Baldwin; Angshu Bhowmik; Neal Navani; Karen Sennett; Stephen W Duffy; Jane Wardle; Jo Waller; Samuel M Janes Journal: Am J Respir Crit Care Med Date: 2020-04-15 Impact factor: 21.405
Authors: H Kitchener; M Gittins; M Cruickshank; C Moseley; S Fletcher; R Albrow; A Gray; L Brabin; D Torgerson; E J Crosbie; A Sargent; C Roberts Journal: J Med Screen Date: 2017-05-22 Impact factor: 2.136
Authors: María José Pérez-Lacasta; Montserrat Martínez-Alonso; Montse Garcia; Maria Sala; Lilisbeth Perestelo-Pérez; Carmen Vidal; Núria Codern-Bové; Maria Feijoo-Cid; Ana Toledo-Chávarri; Àngels Cardona; Anna Pons; Misericòrdia Carles-Lavila; Montserrat Rue Journal: PLoS One Date: 2019-03-26 Impact factor: 3.240
Authors: Samantha L Quaife; Mamta Ruparel; Jennifer L Dickson; Rebecca J Beeken; Andy McEwen; David R Baldwin; Angshu Bhowmik; Neal Navani; Karen Sennett; Stephen W Duffy; Jo Waller; Samuel M Janes Journal: Am J Respir Crit Care Med Date: 2020-10-15 Impact factor: 21.405